Official Journal of the Human Genome Organisation
Table 4 The distribution of renal function for each genotype for the four treatment arms
From: High dose Losartan and ACE gene polymorphism in IgA nephritis
Treatment | Renal failure | ACE | P-value* | ||
|---|---|---|---|---|---|
DD | ID | II | |||
High dose ARB | Improved | 4 (66.67%) | 8 (40%) | 11 (31.42%) | 0.065 |
Stable | 2 (33.33%) | 10 (50%) | 17 (48.57%) | ||
ESRF | 0 (0%) | 2 (10%) | 7 (20%) | ||
Total | 6 (100%) | 20 (100%) | 35 (100%) | ||
Low dose ARB | Improved | 0 (0%) | 5 (31.25%) | 4 (16.67%) | 0.848 |
Stable | 4 (80%) | 8 (50%) | 14 (58.33%) | ||
ESRF | 1 (20%) | 3 (18.75%) | 6 (25%) | ||
Total | 5 (100%) | 16 (100%) | 24 (100%) | ||
ACEI 20 mg | Improved | 2 (15.38%) | 1 (4.54%) | 3 (10.34%) | 0.838 |
Stable | 8 (61.53%) | 13 (59.09%) | 18 (62.07%) | ||
ESRF | 3 (23.08%) | 8 (36.36%) | 8 (27.59%) | ||
Total | 13 (100%) | 22 (100%) | 29 (100%) | ||
ACEI 10 mg | Improved | 2 (33.33%) | 1 (5.56%) | 0 (0%) | 0.037 |
Stable | 3 (50%) | 14 (77.78%) | 8 (61.54%) | ||
ESRF | 1 (16.67%) | 3 (16.67%) | 5 (38.46%) | ||
Total | 6 (100%) | 18 (100%) | 13 (100%) | ||